Ani pharmaceuticals inc (ANIP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows From Operating Activities
Net (loss)/Income

6,094

15,494

-1,076

3,934

15,375

28,747

301

-1,506

-51,608

-46,196

-47,527

Adjustments to reconcile net loss to net cash and cash equivalents provided by operating activities:
Stock-based compensation

9,217

6,782

6,090

6,067

3,856

3,423

36

0

1,177

992

1,254

Deferred taxes

-9,134

-5,180

3,560

-8,911

-1,877

-14,459

0

-

-

-

-

Excess consideration paid over fair value

-

-

-

-

-

-

-

-

-

-

20,192

Depreciation and amortization

44,612

33,742

27,928

22,343

6,900

3,878

1,110

567

148

167

137

Acquired in-process research and development ("IPR&D")

2,324

1,335

0

0

-

-

-

-

-

-

9,000

Stock warrant expense - noncash

-

-

-

-

-

-

-

-

204

65

64

Loss on disposal of property and equipment

-

-

-

-

-

-

0

-

-367

-4

-

Non-cash interest relating to convertible notes and loan cost amortization

7,024

8,465

7,666

7,281

6,831

559

217

-1,071

-

65

-60

Loss on repurchase of Convertible notes

0

-468

0

0

-

-

-

-

-

-

-

Intangible asset impairment charge

75

0

903

6,685

0

0

-

-

-

-

-

Non-cash compensation relating to business combination

-

-

-

-

-

-

4,418

0

-

-

-

Investment impairment charge

-

-

-

-

-

-

-

-

-

286

-

Changes in operating assets and liabilities:
Accounts receivable, net

7,287

4,743

12,893

23,963

4,635

4,784

7,081

327

-

-

-

Inventories, net

7,660

379

-5,356

1,938

5,869

3,468

708

702

-

-

-

Prepaid expenses and other current assets

-403

1,142

17

647

314

558

188

88

-1,682

365

30

Accounts payable

5,039

3,466

3

1,076

-1,027

225

-565

785

-

-

-

Accrued royalties

-3,372

-3,708

-417

6,269

-96

702

-

-

-

-

-

Accrued compensation and related expenses

-

-

-

-

-160

575

-2,854

0

-

-

-

Current income taxes, net

-6,098

6,184

-3,560

3,525

-5,380

4,233

20

-

-

-

-

Accrued government rebates

-73

1,044

2,039

1,260

2,367

2,011

-

-

-

-

-

Returned goods reserve

4,043

4,278

2,518

3,108

1,203

709

-

-

-

-

-

Accrued expenses, accrued compensation, and other

424

968

1,319

1,383

-

-

-

-

-

-

-

Accrued Medicaid rebates

-

-

-

-

-

-

72

-

-

-

-

Accrued expenses and other

-

-

-

-

90

240

-67

205

-

-

-

Convertible note fair value adjustment

-

-

-

-

-

-

-

-

-23

-1,870

33

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

134

3,142

-1,548

Net Cash and Cash Equivalents Provided by Operating Activities

45,631

67,074

39,419

27,472

17,264

22,033

-5,484

-137

-

-

-

Net Cash Used in Discontinued Operation

-

-

-

-

-

-

-195

-142

-

-

-

Net Cash and Cash Equivalents Provided by Operating Activities

-

-

-

-

-

-

-5,289

5

-47,870

-40,097

-18,430

Cash Flows From Investing Activities
Acquisition of WellSpring Pharma Services Inc., net of cash acquired

0

16,467

0

0

-

-

-

-

-

-

-

Changes in restricted cash

-

-

-

-

-

0

-2,260

0

-

-

-

Cash acquired in business combination

-

-

-

-

-

-

18,198

0

-

-

-

Acquisition of product rights, IPR&D, and other related assets

20,914

5,169

97,624

144,494

30,500

34,634

0

-

-

-

-

Redemption of short term investments

-

-

-

-

-

-

-

-

-

-

3,026

Proceeds from sale of fixed assets

-

-

-

-

-

-

-

-

-

3

-

Acquisition of property and equipment, net

6,635

5,743

10,369

4,566

2,183

1,120

191

292

719

63

165

Net Cash and Cash Equivalents Used in Investing Activities

-27,549

-27,379

-107,993

-149,060

-32,683

-35,754

20,267

-292

-719

-60

2,860

Cash Flows From Financing Activities
Borrowings under Term loan agreement

0

0

75,000

0

0

-

-

-

-

-

-

Borrowings under Delayed Draw Term Loan Agreement

118,000

0

0

-

-

-

-

-

-

-

-

Payment of debt issuance and convertible debt repurchase costs

0

1,572

2,737

294

-

-

-

-

-

-

-

Net proceeds from equity offering

-

-

-

-

-

46,680

0

-

-

-

-

Net proceeds from convertible debt offering

-

-

-

-

-

138,243

0

-

-

-

-

Purchase of call option overlay, net

-

-

-

-

-

15,623

0

-

-

-

-

Payment of debt issuance costs

-

-

-

-

0

0

-

261

-

-

-

Payments on Term loan agreement

2,707

2,813

0

0

-

-

-

-

-

-

-

Repayment of line of credit, net

-

-

-

-

-

-

-4,065

1,001

-

-

-

Cash paid for transaction related costs

-

-

-

-

-

-

-

-

-

-

-2,431

Cash received in transaction

-

-

-

-

-

-

-

-

-

-

24,746

Cash paid for convertible note repayment

-

-

-

-

-

-

-

-

1,234

-

-

Proceeds from stock option exercised

5,738

2,978

353

1,570

819

819

0

-

32

2

-

Proceeds from warrant exercise

-

-

-

-

-

750

809

0

24

-

-

Excess tax benefit from share-based compensation awards

-

-

-

617

360

784

0

-

-

-

-

Repurchase of common stock under the stock repurchase program

-

-

-

2,500

0

0

433

0

-

-

-

Repayment of Convertible Notes

118,750

26,125

0

0

-

-

-

-

-

-

-

Unwinding of portion of call option overlay, net

0

375

0

0

-

-

-

-

-

-

-

Treasury stock purchases for restricted stock vests

1,031

659

259

122

113

0

-

-

-

-

-

Net Cash and Cash Equivalents (Used in)/Provided by Continuing Operations

-

-

-

-

-

-

-

740

19,069

8,296

18,097

Net Cash Used in Discontinued Operation

-

-

-

-

-

-

-

-300

-

-

-

Proceeds from issuance of common stock by underwritten offering

-

-

-

-

-

-

-

-

44,961

-

-

Proceeds from issuance of common stock by registered direct offering

-

-

-

-

-

-

-

-

23,876

48,452

11,352

Net Cash and Cash Equivalents Provided by Financing Activities

1,250

-27,816

72,357

-729

1,066

171,653

-3,689

440

67,660

48,454

33,667

Change in Cash, Cash Equivalents, and Restricted Cash

19,332

11,879

3,783

-122,317

-14,353

157,932

11,094

11

-

-

-

Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized

6,092

6,285

3,759

4,078

4,149

0

250

255

688

688

248

Cash paid for income taxes

10,033

6,397

17,786

9,537

13,255

147

0

-

-

-

-

Supplemental non-cash investing and financing activities:
Acquisition of marketing and distribution rights included in accounts payable

500

0

0

-

-

-

-

-

-

-

-

Accrued royalties related to asset purchase

-

-

-

3,882

0

-

-

-

-

-

-

Investment acquired through Cell Genesys transaction

-

-

-

-

-

-

-

-

-

-

3,486

Other assets acquired in Cell Genesys transaction

-

-

-

-

-

-

-

-

-

-

293

Property and equipment purchased and included in accounts payable

723

521

485

247

439

0

0

-

21

-

-

Issuance of common stock in connection with business combination

-

-

-

-

-

-

40,034

0

-

-

36,800

Cancellation of Series D, Series C, Series B, and Series A preferred stock

-

-

-

-

-

-

53,726

0

-

-

-

Acquired non-cash net assets

-

-

-

-

-

-

11,597

0

-

-

-

Assumed liabilities

-

-

-

-

-

-

-

-

-

-

18,487

Preferred stock dividends accrued

-

-

-

-

-

-

4,975

6,922

-

-

-

Issuance of common and preferred stock upon cashless warrant exercise

-

-

-

-

-

-

-

5

-

-

-

Issuance of preferred stock upon convertible debt conversion

-

-

-

-

-

-

-

17,610

-

-

-

Investment - non-cash

-

-

-

-

-

-

-

-

-

65

-